INFO:

In this technical session, Creative Biolabs has invited Dr. Leyton to describe the need to develop a more precise method in investigating nuclear transport dynamics of NLS-therapeutics. Moreover, Dr. Leyton will also present a de novo approach for generating novel NLSs with an atypical zero net-charge and evaluating various strategies to determine the worth for integration into NLS-therapeutics development.